References
- Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005 Apr 1;23(10):2224–2232.
- Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. ASH Educ Program Book 2012 Dec 8;2012(1):571–581.
- Elliott MA, Tefferi A, Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005 Feb 1;128(3):275–290.
- Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F, Clinical course of essential thrombocythemia in 147 cases. Cancer 1990 Aug 1;66(3):549–556.
- De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008 Mar 1;93(3):372–380.
- Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S, Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002 Apr 9;105(14):1650–1655.
- Tefferi A, Barbui T, Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015 Feb 1;90(2):162–173.
- Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004 Jan 8;350(2):114–124.
- Mega JL, Simon T, Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. The Lancet 2015 Jul 24;386(9990):281–291.
- Alvarez-Larran A, Pereira A, Guglielmelli P, Hernandez-Boluda JC, Arellano-Rodrigo E, Ferrer-Marin F, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 2016 Aug 1;101(8):926–931.
- Le Quellec S, Bordet J-C, Negrier C, Dargaud Y. Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response: A review of the literature. Thromb Haemost 2016 Jul 21;116(4):638–650.
- Gillet B, Ianotto J-C, Mingant F, Didier R, Gilard M, Ugo V, et al. Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance. Thromb Res 2016 Jun;142:26–32.
- Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012 Apr 12;119(15):3595–3603.
- Tefferi A, Overcoming “aspirin resistance” in MPN. Blood 2012 Apr 12;119(15):3377–3378.
- Dillinger J-G. Sollier CB dit, Sideris G, Ronez E, Henry P, Drouet L. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocytemia. Thromb Res. 2012 Jan 1;129(1):91–94.
- Halushka MK, Walker LP, Halushka PV, Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003 Jan 1;73(1):122–130.
- Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, et al. WHO classification of tumours of haematopoietic and lymhoid tissues. Lyon, France: IARC Press; 2008.
- Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Beau MML, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 2016 May 19;127(20):2391–405.
- Lebois M, Dowling MR, Gangatirkar P, Hodgkin PD, Kile BT, Alexander WS, et al. Regulation of platelet lifespan in the presence and absence of thrombopoietin signaling. J Thromb Haemost JTH 2016 Sep;14(9):1882–1887.
- Kapoor JR, Enteric Coating Is a Possible Cause of Aspirin Resistance. J Am Coll Cardiol 2008 Oct 7;52(15):1276–1277.